Form 4: Director Saira Ramasastry Executes Stock Option Exercise

Mirum Pharmaceuticals director Saira Ramasastry exercised 2,000 stock options and sold the resulting shares under a 10b5-1 plan.

Summary

• Director Saira Ramasastry exercised 2,000 stock options at a strike price of $23.51 per share.
• The acquired shares were subsequently sold at an average price of $109.47 per share.
• The transactions were executed on May 15, 2026, pursuant to a pre-established Rule 10b5-1 trading plan adopted on September 18, 2025.
• Following these transactions, the director holds zero shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement and represents a standard exercise of vested equity compensation.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading arrangement, which is a standard practice for corporate insiders to avoid concerns regarding non-public information.

Negatives

• The director has liquidated their entire direct holding of 2,000 shares through this transaction.

Risks

• None identified in this specific filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance mechanism in the biotechnology sector, allowing directors to realize gains from equity compensation without signaling negative sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with standard regulatory compliance practices for directors at mid-cap pharmaceutical companies like Mirum Pharmaceuticals.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and limited in volume.

Next Steps

• None mentioned.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Insider Trading, Form 4, Stock Options, Rule 10b5-1